Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, "TRIM," a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies. Tirzepatide, a dual GIP ...

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets Licensed Product / Nation Patent Application Serial No. Title: Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display ...

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, ...

Core Insights - Entera Bio Ltd. and OPKO Health, Inc. announced positive topline pharmacokinetic/pharmacodynamic results from their collaboration on a proprietary long-acting oxyntomodulin (OXM) analog, aimed at developing the first oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders [1][2] Group 1: Collaboration and Research Progress - The collaboration has successfully completed in vivo proof-of-concept PK/PD studies in rodent and pig models, demonstrating significant systemic exposure and favorable pharmacokinetic profiles for oral OXM [2][3] - A glucose tolerance test in rats showed that oral OXM significantly reduced plasma glucose levels compared to placebo, indicating its potential efficacy [3][4] Group 2: Product Development and Market Potential - Entera is developing the first oral oxyntomodulin in tablet form, which could provide a non-injection alternative for obesity treatment, addressing a significant unmet medical need [6] - OPKO's previous studies indicated that weekly injections of pegylated OXM led to significant weight loss and improvements in metabolic markers among obese and diabetic patients, highlighting the therapeutic potential of OXM [5] Group 3: Company Profiles - Entera Bio is focused on developing oral peptide therapies for unmet medical needs, with a pipeline that includes five first-in-class oral peptide programs expected to enter clinical trials by 2025 [6] - OPKO Health is a multinational biopharmaceutical company aiming to establish leading positions in rapidly growing markets through its proprietary technologies and expertise in drug development [7]

SAFETY HARBOR, Fla., Sept. 24, 2024 /PRNewswire/ --- Integrated Ventures Inc. ("Company", "OTCQB: INTV") is pleased to announce that its newly launched subsidiary, MedWell USA, LLC has signed a strategic and valuable Management Services Organization ("MSO") agreement with FDA licensed manufacturer of pharmaceutical products. This agreement enables MedWell USA to act as a Procurement Agent for Semaglutide, a leading pharmaceutical product in the weight management sector. MedWell USA will leverage various mar ...

Company Overview - Terns Pharmaceuticals has a market cap of less than $800 million, with significant potential upside in the anti-obesity market [1] - The company is developing a once-daily GLP-1 pill, TERN-601, which has shown promising early trial results [4] Industry Insights - The anti-obesity market is projected to reach $100 billion by the end of the decade, currently dominated by Eli Lilly and Novo Nordisk [2] - There is a shift towards oral weight-loss treatments, which may be more appealing for long-term use compared to current injection-based therapies [2] Clinical Trial Results - TERN-601 demonstrated a placebo-adjusted mean weight loss of 4.9% at the highest dosage (740mg) over a 28-day trial, with over two-thirds of participants losing more than 5% of their body weight [4] - In comparison, rival Viking Therapeutics' oral drug VK2735 achieved a placebo-adjusted weight loss of up to 3.3% with a much lower dosage of 40mg [5] - Other competitors like Eli Lilly and Novo Nordisk have shown over 13% weight loss in early-stage trials, but over longer periods of 36 to 68 weeks [6] Financial Considerations - Terns has burned through nearly $79 million in operating activities over the past 12 months, indicating ongoing cash flow challenges [8] - The company announced a $150 million offering to raise capital, which is common for stocks experiencing a rally [7] Future Outlook - Terns plans to advance to phase 2 trials for TERN-601 next year, but the path forward may be volatile due to the need for additional funding and competition in the market [6][9] - While the early trial results are encouraging, there is uncertainty regarding the drug's market entry and potential competition from more effective treatments that may emerge [10]

Core Viewpoint - Becton, Dickinson and Company (BD) is positioned for growth through the acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion and the expanding GLP-1 drug delivery market, with a reiterated 'Buy' rating and a fair value of $265 per share [1][18]. GLP-1 Drug Delivery - BD's prefilled syringes and self-administered injection systems are set to capitalize on the rapidly growing GLP-1 drug market, projected to reach $72 billion by 2034 with a CAGR of 11.7% from 2024 to 2034 [2]. - BD has secured a strong market share in the prefilled syringe market, being chosen as a partner for 19 out of 23 new biologic drugs, and has signed 40 GLP-1 biosimilar agreements [3]. - The GLP-1 delivery market is expected to contribute at least $1 billion in revenue by 2030, adding approximately 3% to overall revenue growth [3]. Acquisition of Edwards Lifesciences' Critical Care - The acquisition is seen as value accretive, with the Critical Care business projected to grow at 6%-7% annually and a gross margin exceeding 60% [4]. - BD plans to fund the acquisition with $1 billion in cash and $3.2 billion in new debt, expecting a net debt leverage of 3x post-transaction [4]. - This acquisition is anticipated to enhance BD's technology in monitoring and AI-enabled clinical decision-making, supporting long-term growth in critical care [4]. Recent Results and Outlook - BD reported a 5.2% organic revenue growth and a 22.6% adjusted EPS growth for Q3 FY24, while slightly lowering organic revenue guidance but raising EPS guidance for FY24 [5]. - The Medical Segment is expected to grow by 6%, driven by the GLP-1 drug delivery market, while the Life Sciences Segment is forecasted to grow by 5% as comparable issues from the pandemic fade [5]. - The Interventional Segment is projected to grow by 7%, supported by investments in critical care business units [5]. Valuation - BD is estimated to achieve an 8% total revenue growth in the near future, with a DCF model indicating a fair value of $265 per share [7][15]. - The company anticipates margin expansion through new product launches and operational efficiencies, contributing to overall profitability [7]. Conclusion - The GLP-1 drug delivery market and the acquisition of the Critical Care product group are key drivers for BD's growth, reinforcing a positive outlook with a 'Buy' rating and a fair value of $265 per share [18].

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Higher do ...

Company Overview - Integrated Ventures Inc. has launched a fully funded subsidiary, MedWellDirect, LLC, which focuses on Direct-To-Consumer telemedicine solutions for weight loss and GLP-1 products [1] - The company has acquired a 51% stake in GetTrim.Com, a telemedicine weight loss services provider owned by Healthy Lifestyle USA [1] Industry Positioning - This strategic move positions Integrated Ventures at the forefront of the rapidly expanding medical weight loss industry, driven by increasing consumer adoption of medications like Semaglutide and Tirzepatide [2] - The telemedicine market for weight loss solutions is experiencing significant growth, indicating a strong shift towards these services [4] Platform and Technology - Healthy Lifestyle USA has developed two consumer-targeted platforms, GetTrim.Com and JoinTrim.Com, offering effective weight loss solutions supported by advanced technology and marketing strategies [3] - The platforms utilize a unified, cloud-based architecture that ensures scalability, reliability, and compliance with HIPAA and GDPR regulations [5] Market Reach and Compliance - The GetTrim platform is compliant to operate in 49 states, including major markets such as California, Florida, Texas, and New York, allowing it to reach a broad audience [6] - This extensive reach aligns with Integrated Ventures' growth strategy to become a leading player in the medical weight loss sector [6] Leadership Perspective - The CEO of Integrated Ventures emphasized that the acquisition of GetTrim.Com is central to the company's B2C/D2C growth strategy and reflects its commitment to high-growth sectors [7]

Core Insights - The rise of GLP-1 weight-loss treatments highlights the significance of protein in preventing muscle loss, leading to increased popularity of high-protein diets like keto and carnivore [1] - The addition of beef to restaurant menus has positively impacted sales, with several restaurant stocks benefiting from this trend [1] Company Summaries Sweetgreen - Sweetgreen Inc. has shifted its focus by adding beef options to its menu, which has attracted a broader customer base beyond health-conscious diners [2] - The introduction of grass-fed Caramelized Garlic Steak in Q1 2024 resulted in 20% of dinner orders including steak, contributing to a 5% year-over-year increase in comparable sales, which rose to 9% in Q2 2024 [3] CAVA Group - CAVA Group Inc. reported a remarkable 14.4% year-over-year growth in comparable sales for Q2 2024, alongside a 35.2% increase in revenue and the opening of 78 new restaurants [4] - The rollout of grilled steak, tested in December 2023, was added to the core menu in June 2024, with expectations for significant impact on Q3 2024 earnings [6] Texas Roadhouse - Texas Roadhouse Inc. operates over 700 steakhouse-style restaurants, with beef as its primary offering, and reported a 9.3% year-over-year growth in comparable sales for Q2 2024, outperforming competitors [7][8] Chili's Grill and Bar - Chili's Grill and Bar, owned by Brinker International Inc., achieved a 14.8% year-over-year growth in comparable sales in Q2 2024, largely due to the viral success of its Big Smasher burger [9][12] - The Big Smasher campaign has positioned Chili's as a direct competitor to fast-food chains, leveraging social media for increased visibility and sales growth [11][12]